Private company

Genocea (United States)

American biological products company based in Cambridge, founded in 20061

In its 2022 annual report the company says: “We are a biopharmaceutical company dedicated to discovering and developing novel cancer immunotherapies using our proprietary ATLAS TM platform.”49

Last updated Oct 20, 2026.

Overview

2006Founded1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersCambridge1
  • Websitewww.genocea.com
  • Incorporated inDE3
  • Business address100 Acorn Park Drive, Cambridge, Ma 021403
  • Filer categoryNon-accelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-3174.5%Operating margin4
-2022.9%Net margin4
20.8%Revenue growth, 20214
-122.6%Return on equity4
0.15×Debt to equity4
-$48.7MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Research and development97¢$39.0M
  • Interest3¢$1.1M

Out of $1.6M in revenue.4 The company lost money this year.

Financial statements

Revenue54$1.6M in 2021
0$500.0K$1.0M$1.5M$2.0M2019: $0$020192020: $1.4M$1.4M20202021: $1.6M$1.6M2021+21%
Operating income67854-$52.1M in 2021+26% since 2015
-$60.0M-$40.0M-$20.0M02015: -$41.4M-$41.4M20152016: -$48.2M-$48.2M2016+17%2017: -$55.3M-$55.3M2017+15%2018: -$39.5M-$39.5M2018−28%2019: -$39.0M-$39.0M2019−1%2020: -$47.0M-$47.0M2020+21%2021: -$52.1M-$52.1M2021+11%
Net income67854-$33.2M in 2021−22% since 2015
-$60.0M-$40.0M-$20.0M02015: -$42.5M-$42.5M20152016: -$49.6M-$49.6M2016+17%2017: -$56.7M-$56.7M2017+14%2018: -$27.8M-$27.8M2018−51%2019: -$39.0M-$39.0M2019+40%2020: -$43.7M-$43.7M2020+12%2021: -$33.2M-$33.2M2021−24%
Fiscal year2015201620172018201920202021
Revenue$05$1.4M4$1.6M4
Research and development$28.0M6$34.6M6$39.2M7$25.2M8$27.0M5$34.0M4$39.0M4
Operating expenses$53.7M4
Operating income-$41.4M6-$48.2M6-$55.3M7-$39.5M8-$39.0M5-$47.0M4-$52.1M4
Interest$1.3M6$1.7M6$1.4M7$1.0M8$946.0K5$1.4M4$1.1M4
Net income-$42.5M6-$49.6M6-$56.7M7-$27.8M8-$39.0M5-$43.7M4-$33.2M4
Earnings per share-$1.895-$0.984-$0.484
Earnings per share (diluted)-$1.895-$1.114-$0.484
Shares (weighted, basic)68.6M shares4
Shares (weighted, diluted)68.6M shares4

Compare Genocea (United States) with another company

Corporate structure

Genocea (United States) sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Genocea (United States)

  • New Enterprise Associates 16, L.P. Filed SC 13D/A on Genocea (United States), latest May 27, 2022
  • BIOTECHNOLOGY VALUE FUND L P Filed SC 13G/A on Genocea (United States), latest Feb 14, 2022
  • CITADEL ADVISORS LLC Filed SC 13G/A on Genocea (United States), latest Feb 14, 2022
  • Commodore Capital LP Filed SC 13G/A on Genocea (United States), latest Feb 14, 2022
  • Genocea (United States) Cambridge

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Genocea (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$12.2M4 Dec 31, 2021$12.5M4 Dec 31, 2020−2.4%
Accumulated depreciation$6.4M4 Dec 31, 2021$7.4M4 Dec 31, 2020−13.7%
Property and equipment, net$5.8M4 Dec 31, 2021$5.1M4 Dec 31, 2020+14.0%
Finance-lease assets$04 Dec 31, 2021$30.0K4 Dec 31, 2020−100.0%
Operating-lease assets (leased space)$7.4M4 Dec 31, 2021$9.3M4 Dec 31, 2020−20.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$37.1M4 Dec 31, 2021$79.8M4 Dec 31, 2020−53.4%

Leadership

Who has led Genocea (United States), and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Diantha Duvall2019–2022
2010201520202025
Board members and other officers (25)

Former names

  • GENOCEA BIOSCIENCES INCFeb 25, 2009 to Feb 25, 20093

Timeline

  1. Jun 1, 20228-K Executive or director change37
  2. May 24, 20228-K Listing notice or transfer; Executive or director change; Other events38
  3. Apr 28, 20228-K Exit or restructuring costs; Regulation FD disclosure39
  4. Mar 10, 20228-K Results of operations40
  5. Mar 7, 20228-K Executive or director change41
  6. Jan 4, 20228-K Entered a material agreement; Regulation FD disclosure42
  7. Oct 28, 20218-K Results of operations43
  8. 2006Founded Founded1

Calendar

When it reported results

  1. Mar 10, 2022Reported quarterly or annual results40
  2. Oct 28, 2021Reported quarterly or annual results43

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

75 filings to the SEC since October 2021: 2 annual reports, 2 quarterly reports, 7 major events, 37 insider forms, 4 large holders, 23 other. The latest 20:

  1. Jun 13, 202215-12B EDGAR
  2. Jun 10, 2022EFFECT EDGAR
  3. Jun 10, 2022EFFECT EDGAR
  4. Jun 9, 2022POS AM EDGAR
  5. Jun 9, 2022POS AM EDGAR
  6. Jun 7, 2022EFFECT EDGAR
  7. Jun 7, 2022EFFECT EDGAR
  8. Jun 6, 2022S-8 POS EDGAR
  9. Jun 6, 2022S-8 POS EDGAR
  10. Jun 6, 2022S-8 POS EDGAR
  11. Jun 6, 2022S-8 POS EDGAR
  12. Jun 6, 2022S-8 POS EDGAR
  13. Jun 6, 2022S-8 POS EDGAR
  14. Jun 6, 2022S-8 POS EDGAR
  15. Jun 6, 2022S-8 POS EDGAR
  16. Jun 6, 2022S-8 POS EDGAR
  17. Jun 6, 2022S-8 POS EDGAR
  18. Jun 6, 2022S-8 POS EDGAR
  19. Jun 6, 2022S-8 POS EDGAR
  20. Jun 3, 2022POS AM EDGAR

The 75 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

37 open-market trades by officers, directors and large owners since October 2021: 0 buys and 37 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 2, 2022Duvall DianthaCHIEF FINANCIAL OFFICERSale1,355$0.06$81Form 4
Jun 2, 2022Flechtner Jessica BakerChief Scientific OfficerSale1,578$0.06$95Form 4
Jun 2, 2022Clark William DPresident and CEOSale4,023$0.06$241Form 4
Jun 1, 2022SUMER JACQUELYN LCHIEF LEGAL & COMPLIANCE OFFSale2,500$0.06$150Form 4
May 31, 2022Clark William DPresident and CEOSale117,244$0.06$7.0KForm 4
May 27, 2022Siber GeorgeDirectorSale20,425$0.07$1.4KForm 4
May 26, 2022Duvall DianthaCHIEF FINANCIAL OFFICERSale24,407$0.08$2.0KForm 4
May 25, 2022STAPLETON RAYMOND D JRCHIEF TECHNOLOGY OFFICERSale2,500$0.09$225Form 4
May 25, 2022Flechtner Jessica BakerChief Scientific OfficerSale16,525$0.09$1.5KForm 4
May 25, 2022Walker Paul Edward10% ownerSale4,445,093$0.08$355.6KForm 4
May 25, 2022Sonsini Peter W.10% ownerSale4,445,093$0.08$355.6KForm 4
May 25, 2022SANDELL SCOTT D10% ownerSale4,445,093$0.08$355.6KForm 4
May 25, 2022New Enterprise Associates 16, L.P.10% ownerSale4,445,093$0.08$355.6KForm 4
May 25, 2022Makhzoumi Mohamad10% ownerSale4,445,093$0.08$355.6KForm 4
May 25, 2022Florence Anthony A. Jr.10% ownerSale4,445,093$0.08$355.6KForm 4
May 25, 2022Chang Carmen10% ownerSale4,445,093$0.08$355.6KForm 4
May 25, 2022Behbahani AliDirectorSale4,445,093$0.08$355.6KForm 4
May 25, 2022BASKETT FOREST10% ownerSale4,445,093$0.08$355.6KForm 4
May 24, 2022Walker Paul Edward10% ownerSale5,931,843$0.07$415.2KForm 4
May 24, 2022Sonsini Peter W.10% ownerSale5,931,843$0.07$415.2KForm 4

All 37 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Genocea (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGENOCEA BIOSCIENCES, INC.2
  • CIK0001457612
  • Employer ID (EIN)51-05968112
  • Filer statusNon-accelerated filer<br>smaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
  • Business address100 Acorn Park Drive, Cambridge, MA 021402
  • Phone61787681912
  • Shares outstanding58,783,503 as of Apr 29, 20229
  • Public float$108.8M as of Jun 30, 202148
  • On EDGAR sinceFeb 25, 20092
  • Filings635 in all: 4 (234), 8-K (109), 3 (49), 10-Q (25), SC 13G/A (25), CORRESP (16), SC 13G (14), UPLOAD (13)2
    All 46 form types

    EFFECT (12), S-8 (12), S-8 POS (12), SC 13D/A (11), 10-K (9), 424B5 (8), CT ORDER (7), DEF 14A (7), DEFA14A (7), S-3 (6), 5 (5), D (5), S-1/A (5), 424B2 (4), POS AM (4), PRE 14A (4), SC 13D (4), S-1 (3), 424B3 (2), 424B4 (2), 8-K/A (2), DRSLTR (2), FWP (2), 10-K/A (1), 15-12B (1), 25 (1), 3/A (1), 8-A12B (1), CERTNAS (1), D/A (1), DEFR14A (1), DRS (1), DRS/A (1), NT 10-Q (1), REGDEX (1), RW (1), S-1MEF (1), S-3/A (1)

  • Latest filingsAnnual report (10-K) Mar 18, 2022
    Quarterly report (10-Q) May 5, 2022
    Proxy statement (DEF 14A) Apr 29, 2021
    Latest 8-K (8-K) Jun 1, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49